Introduction
============

Myasthenia gravis (MG) is a relatively rare heterogeneous autoimmune neuromuscular disorder, clinically characterized by weakness and fatigability of skeletal and extraocular muscles.[@b1] MG is a T-cell-dependent antibody-mediated disease, caused by autoantibodies directed against acetylcholine receptor (AChR) in over 80% of patients.[@b2] Patients with early-onset MG (EOMG; disease onset before age 50) form a particularly well-defined subgroup, with a disease prevalence in Europeans of about 10--20 in 100,000 and a strong female bias.[@b3]--[@b5] Pathogenesis in this subgroup involves not only the muscle AChR as the target of the autoimmune response, but also the thymus, which very frequently shows lymph node-like infiltrates.[@b6] EOMG is rarely inherited within a family, but occurrence of other autoimmune and immune-mediated diseases among myasthenia patients\' relatives is relatively common.[@b7] The concordance rate in MG twins is estimated to be 35% in monozygotic twins, compared with 4--5% in dizygotic twins,[@b8] supporting genetic contribution to disease pathogenesis. The current hypothesis is that EOMG is a rare complex disease associated with numerous genetic contributors each having a small effect.[@b9]

Human leukocyte antigen ancestral haplotype (HLA-AH8.1) has been consistently associated with EOMG in Caucasian.[@b4],[@b10] The HLA-AH8.1 haplotype, that tightly associates the various alleles of HLA-A1, B8, DR3 genes, shows an exceptionally strong tendency to be inherited together, making it hard to distinguish the contribution of each individual gene. Remarkably, HLA-AH8.1 haplotype has been associated with several autoimmune diseases, such as celiac, thyroid diseases, and systemic lupus erythematosus, but not with the late-onset MG, supporting the hypothesis of shared genetic risk factors for several autoimmune diseases.[@b11],[@b12] In addition, polymorphisms in AChR alpha (*CHRNA1*) have been shown to confer increased risk to very early-onset MG.[@b13]

In the past 5 years, important biologic discoveries have come from genome-wide association studies (GWAS) aimed at unbiased detection of variants at loci predisposing to complex traits, such as cardiac, autoimmune diseases, and psychiatric disorders.[@b14] Because most such variants have modest effects, they can only achieve genome-wide significance in well-powered GWAS with thousands of samples. A candidate gene approach is a valuable alternative, as it needs only a few hundred samples to highlight even modest genotype-risk associations, with the caveats that it requires some knowledge of disease pathophysiology, knowledge that may be biased.

To identify additional susceptibility loci, we undertook a two-stage study on 34 candidate genes and one confirmation loci and eight genes in the replication stage, of which five showed significant associations as described below.

Materials and Methods
=====================

Study design
------------

The study was designed to identify candidate loci in the exploration stage and check them in a larger group of patients and controls in the replication stage (Fig.[1](#fig01){ref-type="fig"}). We estimated that the study had 0.8 power to detect odds ratios (OR) of ≥2 in the exploration stage and 1.5 in the replication stage, respectively.

![Experimental design workflow.](acn30001-0329-f1){#fig01}

Study subjects
--------------

Following local Ethics Committee approval and informed consent signed, we recruited: (1) Caucasian patients with ocular and generalized MG with anti-AChR antibodies from nine European centres (Table[1](#tbl1){ref-type="table"}) according to these inclusion criteria: males and females diagnosed with MG onset between ages 15 and 50, without thymoma and positive for anti-AChR antibodies[@b15]; (2) healthy age-matched Caucasian controls from six of the same centres, without any other neurological or autoimmune diseases. Samples were recruited from nine European centres, France, Italy, Poland, United Kingdom, Greece, Spain, Germany, Hungary, and Norway. About 1300 anti-AChR-positive EOMG patients were genotyped for the current study, 384 for the exploration stage, and additional 912 for the replication stage. However, about 10% of samples were excluded due to poor DNA quality, genotype quality, or population certification issues. In total, 1177 patients (240 males and 937 females) and 814 controls were used for the statistical analysis (Table[1](#tbl1){ref-type="table"}). The recently published GWAS and the current study shared DNA (those from the United Kingdom, Norway, and some from France); hence, the two studies have some overlap.[@b5]

###### 

European centres involved in DNA sample collection for MG patients and matched controls.

  Centre                                                Country   Male   Female   Total                
  ----------------------------------------------------- --------- ------ -------- ------- ----- ------ -----
  INSERM, Paris                                         France    80     136      270     152   350    288
  INNCB, Milano                                         Italy     44     78       120     90    164    168
  Oslo University Hospital                              Norway    28     38       115     154   143    192
  Medical University of Warsaw                          Poland    22     24       146     24    168    48
  Hellenic Pasteur Institute, Athens                    Greece    16     11       48      53    64     64
  Tübingen University Medical Center                    Germany   14     0        34      0     48     --
  University of Pecs, Pecs                              Hungary   12     0        36      6     48     6
  Weatherall Institute for Molecular Medicine, Oxford   U.K.      15     0        129     0     144    --
  Hospital University of Bellvitge, Barcelona           Spain     9      18       39      30    48     48
  Total                                                           240    305      937     510   1177   814

Candidate gene selection and SNP selection
------------------------------------------

Thirty-four loci, in addition to HLA-DRA, a known susceptibility locus, were selected as candidate genes by team members of groups involved in different research aspects of MG for more than two decades in the framework of a MG European network project (FIGHT-MG). The selection was focused on immune genes, but also included MG-specific candidates, such as the AChR subunits. Both the discovery and replication genotypes of the current study were completed by the time of the EOMG GWAS publication in December 2012,[@b5] hence, the candidate gene selection was not influenced by the GWAS results. To reduce genotyping costs, a small subset of informative SNPs (tag SNPs) was selected using Tagger and JMP-Genomics software.[@b16] Hence, 384 (Table S1) and 95 (Table S2) SNPs were genotyped during the exploration and replication stages, respectively.

Genotype methodology and quality control
----------------------------------------

Genotyping was carried out using Illumina GoldenGate assays for the exploration stage at the Genomics Core Facility (Technion, Haifa, Israel), and the Biomark system (Fluidigm, South San Francisco, CA) for the replication stage at Biological Services (Weizmann Institute for Science, Rehovot, Israel), according to the manufacturer\'s protocols.[@b17],[@b18] SNP assays were designed by Illumina or by Fluidigm SNPtype Assays. Subjects with \<90% successful genotyping or deviating from the expected European clustering were excluded from the analysis, about 10% of the samples. SNPs with minor allele frequencies (MAF) less than 0.05, or not in Hardy--Weinberg equilibrium, or with GenCall score \<0.5 were also excluded from the analysis, about 30% of SNPs.[@b19] Population substructure was determined using principal component analysis and 24 SNPs used to infer population ancestry (genomic control SNPs) (Table[2](#tbl2){ref-type="table"}).[@b20] The *F*~ST~ score, that is, the contribution by each centre (the S subscript) to the total genetic variance (the T subscript), was about 0.02, which is as expected for a European population, and implies a high degree of similarity among cohorts.[@b21]

###### 

Gene symbol and number of SNPs selected for EOMG association test.

  Symbol         No. SNP   Symbol          No. SNP   Symbol                          No. SNP
  -------------- --------- --------------- --------- ------------------------------- ---------
  *AIRE*         4         *CHRNE*         4         *IL6*                           9
  ***AKAP12***   15        *CXCL13*        18        ***IL7R***                      7
  *C2*           4         *FGF11*         2         *IRF3*                          3
  *CCL21*        4         *FOXP3*         9         *LTA*                           5
  *CD40*         7         ***HLA-DRA***   16        *MUSK*                          30
  *CD40LG*       14        *IFIH1*         8         *MYD88*                         3
  ***CD80***     24        *IFNB1*         2         ***BAFF***                      11
  ***CD86***     15        *IFNG*          3         ***VAV1***                      25
  *CFB*          11        *IL17A*         9         *TLR3*                          8
  *CHRNA1*       6         *IL17RA*        16        *TSLP*                          5
  *CHRNB1*       5         ***IL18***      9         ***TNF***                       8
  *CHRND*        2         *IL2RA*         30        European ancestry marker SNPs   24

In bold loci selected for the replication stage.

Statistical analyses
--------------------

We used JMP-Genomics V6 software (SAS Institute, Cary, NC) to compare allele frequencies between cases and controls; differences were considered significant when *P*-values were \<0.05 after false discovery rate (FDR) adjustment. ORs and 95% confidence intervals (CI) were calculated for statistically significant SNPs. Linkage disequilibrium (LD) blocks and SNP haplotypes were inferred using the Expectation--Maximization algorithm, as implemented in JMP-Genomics. Haplotype trends and SNP↔SNP interactions were tested using the same software.

Results
=======

Analysis of the exploration stage genotype data identified significant associations in EOMG with eight of the 34 genes tested, and confirmed the known associations at *HLA-DRA*.[@b4],[@b10] However, no difference in allele frequency between EOMG and controls were found for SNPs in AChR subunits or for SNPs in the genomic region of the autoimmune regulator (*AIRE*).[@b13] It is possible that some of the candidate genes may still be found to associate with EOMG if tested in larger study, because of the limited statistical power of the exploration stage. Complete analyses of the combined exploration and replication cohorts identified 10 SNPs, in six genes, showing significant associations (Table[3](#tbl3){ref-type="table"}): HLA class II DR *α* chain (***HLA-DRA***); tumor necrosis factor-*α* (***TNF-α***), both part of the extended HLA-AH8.1 haplotype; A kinase (PRKA) anchor protein 12 (***AKAP12*** or *gravin*)*; **CD86*** antigen (CD28 antigen ligand 2, B7-2 antigen); vav 1 guanine nucleotide exchange factor (***VAV1**)*; TNF ligand superfamily member 13B (***TNFSF13B***), also known as B-cell activating factor ***(BAFF)***. Analysis of one representative SNP per gene shows differences from the controls that were consistently in the same direction and with similar delta values in each European Center for SNPs in: ***HLA-DRA***; ***TNF-α***; ***BAFF***; ***VAV1*** (Fig.[2](#fig02){ref-type="fig"}). In particular, the consistent 4--5% differences between EOMG and controls in MAFs at *BAFF* (despite the marginally significant *P*-value of 0.045 for the trend test) suggest that this is most likely a true association that requires further investigation. The differences at *CD86* and *AKAP1*2 were less consistent between centres, possibly due to their low MAFs.

###### 

Significantly associated SNPs with allele frequencies and odds ratio estimate.

  SNP_ID       Locus_ID    MAFs frequency   FDR corrected negLog~10~ *P*-value   Odds ratio and 95% CIs                         
  ------------ ----------- ---------------- ------------------------------------ ------------------------ ------- ------ ------ ------
  rs3129882    *HLA-DRA*   0.48             0.42                                 2.58                     2.76    0.78   0.68   0.89
  rs2239806    *HLA-DRA*   0.14             0.32                                 32.00                    31.59   3.07   2.56   3.68
  rs3129888    *HLA-DRA*   0.18             0.14                                 1.75                     2.42    0.72   0.60   0.87
  rs1800629    *TNF*       0.13             0.33                                 32.00                    32.00   3.53   2.92   4.25
  rs1124264    *AKAP12*    0.15             0.09                                 5.40                     6.19    0.56   0.69   0.46
  rs17080949   *AKAP12*    0.07             0.15                                 5.43                     7.31    1.88   1.53   2.32
  rs9282641    *CD86*      0.08             0.04                                 5.35                     5.35    0.45   0.61   0.34
  rs347033     *VAV1*      0.26             0.19                                 3.95                     4.70    0.68   0.58   0.80
  rs4807102    *VAV1*      0.28             0.24                                 1.16                     1.59    0.80   0.69   0.93
  rs9514827    *BAFF*      0.33             0.29                                 1.16                     1.30    0.82   0.95   0.71

Columns 5 and 6 show *P*-values for genotype and additive trend tests after FDR correction, expressed as negative log~10~ values, higher numbers reflecting stronger significance. ORs estimates the protective (values \<1) or the predisposing (values \>1) contributions to disease risk with 95% CIs.

![Analysis of MAFs across populations from different European centres for EOMG (♦) and controls (◊). Horizontal lines indicate medians, \**P*\<0.05; \*\**P*\<0.01 by Mann--Whitney test.](acn30001-0329-f2){#fig02}

Previous reports suggest an interaction between gender and HLA-alleles. Our data clearly confirm that the associations were even stronger at both the *HLA-DRA* and *TNF-α* loci in the 937 females, but were still significant in the 240 males (Fig.[3](#fig03){ref-type="fig"}), with ORs of ∼4 and ∼2, respectively. We found no such gender differences at the other four loci.

![MAFs for six associated genes by gender in patients and controls: \**P*\<0.05; \*\**P*\<0.01, \*\*\**P*\<0.001 by *χ*^2^ tests.](acn30001-0329-f3){#fig03}

"LD blocks" or "haplotypes" are often more informative than single SNPs, because they are more likely to include causative as well as marker variants. When we defined such haplotypes and compared their frequencies (Table[4](#tbl4){ref-type="table"}), we noted the expected LD and frequency differences between the three SNPs spanning the 1 Mb in the HLA-AH8.1 haplotype between the *TNF-α* promoter and the *HLA-DRA* region. The 90 Kbp genomic region on chromosome 19 that harbors *VAV1* has a fragmented pattern of haplotype blocks, each with ≤2 SNPs, and several other SNPs located between them (Fig.[4](#fig04){ref-type="fig"}). The LD block between rs4807102 and rs3786688 creates three possible haplotypes (H1, H2, and H4); of these, H4 was less frequent in EOMG cases (*P* = 0.0015), but the others showed no differences (Table[4](#tbl4){ref-type="table"}). In *BAFF*, three SNPs in the promoter and 5′ coding regions are in LD. They create four possible haplotypes (H2, H3, H4, and H6); of these, H2 was less frequent in EOMG than control subjects (*P* = 0.005; Table[4](#tbl4){ref-type="table"}, Fig.[5](#fig05){ref-type="fig"}). Overall, the haplotype trend test supports the differences in allele frequencies between cases and controls shown in Table[3](#tbl3){ref-type="table"}, but none showed stronger effects than its top-ranking component SNP.

###### 

Haplotype frequency between cases and controls with confidence interval and *P*-value.

  Locus ID            H_ID                                           Haplotype    Haplotype frequencies   *χ*^2^     FDR adjusted *P*-value   
  ------------------- -------- ------------------------------------- ------------ ----------------------- ---------- ------------------------ -------------
  ***TNF_HLA-DRA***   **H1**   rs1800629- rs3129882- rs2239806       **A_A\_A**   **0.07**                **0.25**   **182.05**               **\<0.001**
  *TNF_HLA-DRA*       H2       rs1800629- rs3129882- rs2239806       G_A\_A       0.06                    0.06       0.04                     0.843
  ***TNF_HLA-DRA***   **H3**   rs1800629- rs3129882- rs2239806       **G_A\_G**   **0.36**                **0.25**   **52.57**                **\<0.001**
  ***TNF_HLA-DRA***   **H4**   rs1800629- rs3129882- rs2239806       **G_G\_G**   **0.44**                **0.35**   **28.32**                **\<0.001**
  ***AKAP12***        **H1**   **rs1124264-rs17080949**              **C_C**      **0.15**                **0.09**   **31.52**                **\<0.001**
  ***AKAP12***        **H3**   **rs1124264-rs17080949**              **T_C**      **0.48**                **0.52**   **4.87**                 **0.027**
  *AKAP12*            H4       rs1124264-rs17080949                  T_T          0.37                    0.39       2.14                     0.143
  ***CD86***          **H1**   **rs17203439-rs9282641-rs3792285**    **A-C-C**    **0.08**                **0.04**   **25.07**                **\<0.001**
  *CD86*              H2       rs1800629- rs3129882- rs2239806       G-A-T        0.12                    0.12       0.09                     0.760
  ***CD86***          **H3**   **rs1800629- rs3129882- rs2239806**   **G-C-C**    **0.72**                **0.76**   **5.53**                 **0.020**
  *CD86*              H4       rs1800629- rs3129882- rs2239806       G-C-T        0.08                    0.08       0.01                     0.940
  *VAV1*              H1       rs4807102-rs3786688                   A_A          0.37                    0.40       2.72                     0.099
  *VAV1*              H2       rs4807102-rs3786688                   A_G          0.34                    0.36       0.95                     0.329
  ***VAV1***          **H4**   **rs4807102-rs3786688**               **G_G**      **0.28**                **0.23**   **10.03**                **0.001**
  ***BAFF***          **H2**   **rs9514827- rs9514828-rs17564816**   **C_T\_G**   **0.32**                **0.28**   **7.89**                 **0.005**
  *BAFF*              H3       rs9514827- rs9514828-rs17564816       T_C\_A       0.17                    0.17       0.10                     0.750
  *BAFF*              H4       rs9514827- rs9514828-rs17564816       T_C\_G       0.33                    0.35       2.14                     0.144
  *BAFF*              H6       rs9514827- rs9514828-rs17564816       T_T\_G       0.17                    0.18       0.36                     0.548

Locus ID -- designations of linked loci haplotype.

Significant haplotypes are in bold

![Graphical presentation of the SNP locations and LD structure of *VAV1* gene. (A) Chromosome 19 schematic cytogenetic map. (B) Physical map, with exons marked by blocks and SNPs by lines, plus physical coordinates. (C) LD plot. The strength of LD (*r*^2^) between all possible pairs of SNPs is indicated by the shade of color, ranging from dark blue (very low) to bright red (very high). (D) Haplotype frequencies of *VAV1* in EOMG and controls, and *P*-value for the comparison between groups. H-ID denotes haplotype ID between rs4808102 and rs3786688 SNPs.](acn30001-0329-f4){#fig04}

![Graphical representation of the SNP locations and LD structure of *BAFF* gene. (A--C) Chromosome 13 schematic cytogenetic map, physical map and LD plot as described in Figure[4](#fig04){ref-type="fig"}. (D) Frequencies of haplotypes (H-ID) of the indicated *BAFF* SNPs in EOMG and controls, plus *P*-values for differences between them.](acn30001-0329-f5){#fig05}

Individual SNPs that tag specific genomic regions may predispose independently; alternatively, SNPs from different genomic regions may interact "epistatically", that is conferring a greater risk in combination than by themselves. We identified a significant interaction between rs2617819 in VAV1 and two SNPs (rs9514827 and rs9514828) in the promoter of region of *BAFF* at a *P*-value of 0.03 after correcting for multiple comparisons. Moreover, in carriers of the associating C allele of *VAV1* rs2617819, three of the BAFF haplotype combinations (H3, H4, and H6) were increased in EOMG (Fig.[6](#fig06){ref-type="fig"}). These results suggest that epistatic interactions between *VAV1* and *BAFF* alleles confer a higher risk of EOMG than either does alone.

![BAFF genotype and haplotype frequencies on the background of VAV1 SNP rs2617819. (A) Percentages and numbers (between brackets) of controls and EOMG patients homozygous for either rs9514827 TT or rs9514828 CC by *VAV1* rs2617819 genotype. (B). Percentages of the indicated haplotype combinations in carriers of *VAV1* rs2617819 C allele in controls and EOMG.](acn30001-0329-f6){#fig06}

Discussion
==========

This study shows significant frequency differences between EOMG and controls in four genes, *CD86*, *AKAP12*, *VAV1*, and *BAFF,* and the expected strong associations at *HLA-DRA* and *TNF*. Three of the genes, *CD86*, *VAV1*, and *BAFF*, use the same NFκB signaling pathway. Moreover, *VAV1* and *BAFF* interact epistatically, conferring a greater risk in combination than by themselves. In addition, we confirmed the stronger association with the HLA-AH8.1 haplotype in females; that with rs1800629 (TNF-308G\>A) is of particular interest because of its functional effect on expression levels.[@b4],[@b5],[@b22] By contrast, the role of *AKAP12*, a cell growth-related protein, in EOMG remains elusive. Autoantibodies against it were noted in EOMG patients more than two decades ago, hence its other name is "gravin," but it has since been studied more in the context of cell cycle and malignancy than of myasthenia.[@b23]--[@b25]

There is mounting evidence implicating *BAFF* in the pathogenesis of several autoimmune diseases, including MG.[@b26] Increased serum levels and expression of *BAFF* and its receptors have been demonstrated in the thymus of MG patients[@b27]. *BAFF* promotes the survival, growth, and maturation of B-cells, including autoreactive B-cells and rescue B-cells from apoptosis, thereby contributing to autoimmunity.[@b28] Its exact role in EOMG pathogenesis is not clear. If it proves to be more important in disease initiation than progression, it might become a therapeutic target for novel early intervention in EOMG.[@b29]

*VAV1* is specifically expressed in hematopoietic cells, and is a critical regulator of T-cell cycle progression and proliferation at an early point after convergence of the signaling routes triggered by the T-cell receptor and CD28.[@b30],[@b31] In rats, Vav1 variants control susceptibility to central nervous system (CNS) inflammation by influencing Treg development[@b32] and production of inflammatory cytokines by effector T-cells.[@b33] Several cohorts of patients with multiple sclerosis (MS) have shown associations with *VAV1* haplotypes[@b34]; we also included these here because of their potential impact on T-cell function. Indeed, one of them showed a protective effect by itself in EOMG, whereas another predisposed synergistically with two adjacent SNPs in the *BAFF* promoter.

The immune system shows such marked genotypic and phenotypic complexity that it must be fertile soil for epistasis. Elucidating these interactions at functional as well as genetic levels is key to understanding predisposition to autoimmune diseases.[@b35] Epistatic effects have proved to be central in several model organisms and several autoimmune diseases. They can operate at various levels, ranging from direct interactions between proteins, or between regulatory components in different pathways, where strict partitioning is rare. In immune responses, interactions between antigen receptors and their binding partners, between cytokines and their receptors and between signaling molecules in cell activation cascades are all candidates for genetic epistasis. The example that we now show between *VAV1* and *BAFF* probably represents just one of a multitude of similar interactions that influence disease risk.

Activation of the noncanonical NFκB signaling pathway by *VAV1* increases the expression of *IL-8*, *BAFF,* and *Bcl-xL* genes and might contribute to EOMG predisposition.[@b30] CD86 and TNF-*α*, two other EOMG risk factors noted here, also converge on the activation of NFκB cascade. Notably, the choice of candidate genes was based on preselection of immune genes and therefore the involvement of nuclear factor-kappaB (NF-κB) that acts at the crossroads of many signaling pathways retrospectively is not totally surprising. This is also in light of the fact that NFκB plays a crucial role in the establishment of both central tolerance and the peripheral function of Treg cells, and multiple associations have been found between genes involved in NFκB signaling and autoimmune diseases.[@b36] Thus, defective or dysregulated activation of NFκB pathways, as suggested in the present study seem highly plausible contributors to autoreactivity and inflammation in EOMG.

GWAS of MG is a challenge because of its low prevalence and the modest effect sizes anticipated. Nevertheless, a GWAS with more than 600 patients from northern Europe has found that TNFAIP3-interacting protein 1 (TNIP1) is associated with EOMG and confirms the known association with HLA-B08 and protein tyrosine phosphatase nonreceptor 22 (PTPN22).[@b5] TNIP1, also known as ABIN-1, is thought to be involved in ubiquitin-dependent dysregulation of NF-κB signalling[@b37],[@b38] and corepression of nuclear receptors\' such as retinoic acid receptors and peroxisome proliferator-activated receptors.[@b39] As by the time of the GWAS publication in December 2012[@b5] both the discovery and replication genotypes of the current study were completed, PTPN22 and TNIP1 were not included in the current study as candidate genes. Nevertheless, it is interesting to note that both studies converge on the same signaling pathway, namely NF-κB, in an independent manner.

There is exceptionally strong LD across the entire 4 Mb of the HLA-AH 8.1 haplotype, which is very rich in genes, many with immunological functions. Obviously, with the highly focused SNPs used here, we could not map the association in EOMG precisely. Intriguingly, of the many possible candidate HLA-complex loci, the rs1800629 risk allele in the *TNF* promoter seems particularly relevant. This functional variant correlates with overexpression and oversecretion of the cytokine in vitro and in vivo[@b22],[@b40] and associates with numerous autoimmune diseases including EOMG.[@b41]--[@b44] TNF-*α* overexpression has been implicated in the development of experimental autoimmune MG onset which is prevented by anti-TNF-*α* antibodies.[@b45],[@b46] In addition, an autocrine loop involving TNF-*α* contributes to the production of *AKAP12* mRNA in response to inflammation.[@b47] We suggest that overexpression of TNF-*α* in EOMG patients carrying (-308G\>A) may perpetuate the inflammatory response in the thymus, where Treg cell suppressive function is lacking.[@b48] Indeed, TNF-*α* is increased in both thymic T-cells and sera of EOMG patients, and appears to be involved in the defective regulation observed in these patients.[@b49] Several TNF-*α* inhibitors are widely used to treat autoimmune diseases such as RA, Crohn\'s disease, and psoriasis. Hence, if this functional variant proves to be crucial in EOMG patients, these inhibitors might become important alternative options for them too.

Women are disproportionately affected by autoimmune diseases, especially those with onset between puberty and the menopause. The current study confirmed the gender bias at the HLA loci originally noted by Janer et al. and more recently by Gregersen et al.[@b4],[@b5] Interestingly, we also found a very strong gender bias at the TNF loci, that has not been shown previously, and was confirmed in all our nine cohorts. Sex hormones play a pivotal role in the gender bias with a commonly accepted view that androgens are protective. In an animal model for type 1 diabetes, a hormone-dependent differences in microbiota composition in males were found, and these differences were shown to be protective.[@b50] In addition, X-chromosome transcripts were shown to regulate the transcription of autosomal genes, and affect molecular pathways such as DNA methylation, glucose and protein metabolism in a gender-biased manner.[@b51] Last, but not least, numerous HLA-region genes, including HLA-DRA and TNF, contain estrogen response elements.[@b52] Polymorphisms in these response elements might influence transcription in a gender specific manner. Our study highlights the need for more detailed analysis of the effects of sex differences in immune responses.

In conclusion, our findings implicate several genes converging on the proinflammatory NF-κB signaling pathway. Patients DNA samples were assembled from nine different European centres with a total of 1200 samples genotyped, the most robust genetic study that has been conducted to date in MG in terms of number of patients analyzed. With its larger numbers (1177 vs. 649) and wider geographic spread across Europe, our study complements the recent GWAS,[@b5] which could not detect loci with modest ORs, such as *VAV1* and *BAFF*; conversely, the limited number of loci evaluated in the current study did not include *PTPN22* and *TNIP1* loci. These genetic findings shed light on underlying disease mechanisms in MG and provide targets for the development of novel diagnostic and therapeutic tools for future use in this chronic inflammatory and autoimmune disorder.
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